Introduction Predictive cancer biomarkers to guide the proper treatment to the proper patient at the proper period are strongly required. and HER2 detrimental) and anthracycline reactive (all the cases). Results Altogether, 288 tumors had been designed for TIMP-1 evaluation with (183/274) 66.8%, and (181/274) 66.0% being classed as 2T and HT responsive, respectively. TIMP-1 was… Continue reading Introduction Predictive cancer biomarkers to guide the proper treatment to the